Chinese biotech firm Bao Pharmaceuticals has secured over $100 million in a Series B round of financing led by Oriental Fortune Capital to ramp up its efforts to develop and commercialise recombinant protein drugs and antibody drugs.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
